Illumeo System
Philips Medical Systems Technologies, Ltd. • Radiology • 01/12/2018
Device Purpose
The Illumeo system is an advanced software solution designed for comprehensive medical image management, enabling radiologists to acquire, process, visualize, and analyze multi-modality imaging and associated clinical data for enhanced diagnostic interpretation. It achieves this through a client-server architecture, DICOM compliance, sophisticated image processing tools, and features like an enterprise viewer and improved PACS integration, all aimed at optimizing clinical workflow and supporting detailed patient assessment.
Summary
The Illumeo system, developed by Philips Medical Systems, is an advanced image management software designed for trained medical professionals, primarily radiologists. Its fundamental purpose is to facilitate the acquisition, storage, distribution, processing, and display of medical images and associated patient data within a clinical setting. Operating on general-purpose computing hardware, the system employs sophisticated digital image processing techniques, enabling users to perform measurements, manipulate images, and quantify findings from a wide array of imaging modalities including CT, MR, US, XA, PET, and SPECT. It also integrates non-imaging data, presenting a comprehensive patient context for improved diagnostic interpretation, though it is explicitly not intended for mammography applications. The Illumeo system represents an evolution of the previous I4 system, incorporating significant enhancements to improve clinical workflow and diagnostic capabilities. Key modifications include improved software performance through dedicated PACS interfaces and automatic preprocessing, enhanced integration with IntelliSpace PACS via FHIR, and increased scalability to support up to 150 concurrent users with its HTML5-based enterprise viewer. The system features advanced tools for 2D/3D viewing, findings creation with change tracking, sophisticated image comparison and synchronization, user-defined hanging protocols, and specialized vascular inspection modes. Its technological basis relies on client-server architecture, DICOM standard compliance, and robust data management. Non-clinical performance testing confirmed the system's adherence to relevant ISO and IEC standards for software, risk management, and usability, demonstrating that these modifications maintain safety and effectiveness.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the "Match finding" feature quantify changes over time, and what is the underlying algorithm for lesion tracking and comparison?; What specific improvements in the FHIR interface enhance data retrieval and reporting workflow efficiency when integrated with IntelliSpace PACS, EMR, and RIS?; Can the system's automatic preprocessing capabilities be customized based on imaging modality or specific clinical protocols to optimize image quality or radiologist reading time?; What are the performance benchmarks for the HTML5-based Enterprise Viewer with 150 concurrent users, particularly concerning image loading times and interactive tool responsiveness across different network conditions?; How does the Illumeo system handle potential discrepancies or conflicts when integrating non-imaging data (e.g., lab results, prior findings) from various sources with current imaging studies?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly